Swiss pharma major Novartis on Wednesday updated its mid-term guidance as it reported a fourth-quarter net income of $8.48 billion, up from last year’s $1.47 billion. Earnings per share were $4.14, significantly higher than $0.69 a year ago. Looking ahead for fiscal 2024, the company projects net sales to grow mid single digit and core operating income to grow high single digit. Further, the company updated mid-term guidance, with net sales expecting to grow 5% cc CAGR 2023-2028 with core operating income margin expanding to around 40% by 2027. The latest results included net income from disco…